Legend Biotech USA Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
3,300
- Stock Symbol
-
LEGN
- Share Price
-
$18.54
- (As of Thursday Closing)
Legend Biotech USA General Information
Description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Contact Information
Website
www.legendbiotech.comCorporate Office
- 77 Corporate Drive
- 4th Floor
- Bridgewater, NJ 08807
- United States
Corporate Office
- 77 Corporate Drive
- 4th Floor
- Bridgewater, NJ 08807
- United States
Legend Biotech USA Timeline
Legend Biotech USA Stock Performance
As of 12-Nov-2026, Legend Biotech USA’s stock price is $18.54. Its current market cap is $3.6B with 194M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $18.54 | $19.54 | $16.24 - $37.50 | $3.6B | 194M | 2.21M |
Legend Biotech USA Financials Summary
As of 30-Sep-2026, Legend Biotech USA has a trailing 12-month revenue of $1.36B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,181,975 | 3,432,798 | 5,103,670 | 9,864,965 |
| Revenue | 1,358,500 | 1,028,900 | 627,300 | 285,100 |
| EBITDA | 74,000 | (272,400) | (176,300) | (534,400) |
| Net Income | (200) | (296,800) | (177,000) | (518,300) |
| Total Assets | 1,681,400 | 1,733,700 | 1,670,200 | 1,848,609 |
| Total Debt | 167,400 | 413,700 | 350,600 | 328,672 |
Legend Biotech USA Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Legend Biotech USA Comparisons
Industry
Financing
Details
Legend Biotech USA Competitors (7)
One of Legend Biotech USA’s 7 competitors is Cellectis, a Formerly VC-backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cellectis | Formerly VC-backed | Paris, France | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Autolus | Formerly VC-backed | London, United Kingdom | ||||
| Innovent Biologics | Formerly VC-backed | Suzhou, China |
Legend Biotech USA Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Legend Biotech USA Patents
Legend Biotech USA Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026219173-A1 | Engineered cells and methods of use thereof | Pending | 14-Apr-2025 | ||
| WO-2026208986-A1 | Single-chain fusion hla class i proteins and uses thereof | Pending | 02-Apr-2025 | ||
| WO-2026201170-A1 | Engineered t cells with cd1d-targeting tcr and uses thereof | Pending | 28-Mar-2025 | ||
| WO-2026200862-A1 | Fcrh5 binding molecule and methods of use thereof | Pending | 24-Mar-2025 | ||
| WO-2026184680-A1 | Anti-cd3 antibodies and uses thereof | Pending | 05-Mar-2025 | A61P35/00 |
Legend Biotech USA Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Legend Biotech USA Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Legend Biotech USA ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
27.16 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Legend Biotech USA FAQs
-
When was Legend Biotech USA founded?
Legend Biotech USA was founded in 2014.
-
Where is Legend Biotech USA headquartered?
Legend Biotech USA is headquartered in Bridgewater, NJ.
-
What is the size of Legend Biotech USA?
Legend Biotech USA has 3,300 total employees.
-
What industry is Legend Biotech USA in?
Legend Biotech USA’s primary industry is Biotechnology.
-
Is Legend Biotech USA a private or public company?
Legend Biotech USA is a Public company.
-
What is Legend Biotech USA’s stock symbol?
The ticker symbol for Legend Biotech USA is LEGN.
-
What is the current stock price of Legend Biotech USA?
As of 12-Nov-2026 the stock price of Legend Biotech USA is $18.54.
-
What is the current market cap of Legend Biotech USA?
The current market capitalization of Legend Biotech USA is $3.6B.
-
What is Legend Biotech USA’s current revenue?
The trailing twelve month revenue for Legend Biotech USA is $1.36B.
-
Who are Legend Biotech USA’s competitors?
Cellectis, Allogene Therapeutics, Sorrento Therapeutics, Autolus, and Innovent Biologics are some of the 7 competitors of Legend Biotech USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
